Systemic lupus erythematosus: clinical manifestations, treatment and economics

References

• Petri M. Epidemiology of systemic lupus erythematosus. Best Prac. & Res. Clin. Rheumatol.16(5), 847–858 (2002).
   PubMed Web of Science ®Google Scholar
• Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J. Rheumatol.27, 685–691 (2000).
   PubMed Web of Science ®Google Scholar
• Gudmundsson S, Steinsson K. Systemic lupus erythematosus in Iceland 1975 through 1984. A nationwide epidemiological study in an unselected population. J. Rheumatol.17(9), 1162–1167 (1990).
   PubMed Web of Science ®Google Scholar
• Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br. J. Rheumatol.29(3), 185–188 (1990).
   PubMedGoogle Scholar
• Nightingale AL, Farmer RD, de Vries CS. Incidence of clinically diagnosed systemic lupus erythematosus 1992–1998 using the UK General Practice Research Database. Pharmacoepidemiol. Drug Saf.15(9), 656–661 (2006).
   PubMedGoogle Scholar
• Uramoto KM, Michet CJ Jr, Thumboo J, Sunku J, O’Fallon WM, Gabriel SE. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum.42(1), 46–50 (1999).
   PubMed Web of Science ®Google Scholar
• Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann. Rheum. Dis.53(10), 675–680 (1994).
   Google Scholar
• Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum.38(4), 551–558 (1995).
   PubMed Web of Science ®Google Scholar
• Maskarinec G, Katz AR. Prevalence of systemic lupus erythematosus in Hawaii: is there a difference between ethnic groups? Hawaii Med. J.54(2), 406–409 (1995).
   PubMedGoogle Scholar
• Gladman D, Urowitz MB. Connective tissue disorders: systemic lupus Erythematosus: clinical features. In: Rheumatology. Hochberg MC, Silman AJ, Smolen J, Weinblatt ME, Weisman MH (Eds). Elsevier, Philidelphia, USA, 1359–1380 (2005).
   Google Scholar
• Petri M. Systemic lupus erythematosus. In: Clinical Primer of Rheumatology. Koopman WJ, Bouleware DW, Heudebert GR (Eds). Lippincott Williams & Wilkins, Philadelphia, USA, 164–170 (2003).
   Google Scholar
• Appel GB, Silva FG, Pirani CL, Meltzer JI, Estes D. Renal involvement in systemic lupud erythematosus (SLE), a study of 56 patients emphasizing histologic classification. Medicine (Baltimore)57(5), 371–410 (1978).
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J. Am. Soc. Nephrol.15(2), 241–250 (2004).
   PubMed Web of Science ®Google Scholar
• The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum.42(4), 599–608 (1999).
   PubMed Web of Science ®Google Scholar
• Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N. Engl. J. Med.346(10), 752–763 (2002).
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol.145(5), 408–415 (1997).
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum.44(10), 2331–2337 (2001).
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.25, 1271–1277 (1982).
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum.40, 1725 (1997).
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol.56(7), 481–490 (2003).
   PubMed Web of Science ®Google Scholar
• Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum.46(11), 2924–2927 (2002).
   PubMed Web of Science ®Google Scholar
• Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol.76, 227–324 (2000).
   PubMed Web of Science ®Google Scholar
• Munoz LE, Gaipl US, Franz S et al. SLE a disease of clearance deficiency? Rheumatology (Oxford)44(9), 1101–1107 (2005).
   PubMed Web of Science ®Google Scholar
• Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for SLE. Nat. Rev. Drug Discov.3(12), 1036–1046 (2004).
   PubMedGoogle Scholar
• Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum.43(8), 1801–1808 (2000).
   PubMed Web of Science ®Google Scholar
• Tsakonas E, Joseph L, Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus7(2), 80–85 (1998).
   PubMed Web of Science ®Google Scholar
• Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J. Rheumatol.27(9), 2142–2145 (2000).
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA III, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med.125(7), 549–557 (1996).
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum.46(8), 2121–2131 (2002).
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med.353(21), 2219–2228 (2005).
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med.350(10), 971–980 (2004).
   PubMed Web of Science ®Google Scholar
• Bruce IN. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract. Res. Clin. Rheumatol.19(5), 823–838 (2005).
   PubMedGoogle Scholar
• Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol.19(5), 859–878 (2005).
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum.50(8), 2580–2589 (2004).
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum.50(11), 3580–3590 (2004).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum.46(10), 2673–2677 (2002).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis.61(10), 883–888 (2002).
   PubMed Web of Science ®Google Scholar
• Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther.8(3), R74 (2006).
   PubMed Web of Science ®Google Scholar
• Strand V, Aranow C, Cardiel MH et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus12(9), 677–686 (2003).
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Tumlin JA. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus13(5), 323–327 (2004).
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Dayan M, Tcherniack A et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin. Exp. Immunol.131(2), 385–392 (2003).
   PubMed Web of Science ®Google Scholar
• Wiesendanger M, Stanevsky A, Kovsky S, Diamond B. Novel therapeutics for systemic lupus erythematosus. Curr. Opin. Rheumatol.18(3), 227–235 (2006).
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum.48(3), 719–727 (2003).
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum.46(12), 3251–3258 (2002).
   PubMed Web of Science ®Google Scholar
• Gescuk BD, Davis JC Jr. Novel therapeutic agents for systemic lupus erythematosus. Curr. Opin. Rheumatol.14(5), 515–521 (2002).
   PubMed Web of Science ®Google Scholar
• Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum.42(12), 2682–2688 (1999).
   PubMed Web of Science ®Google Scholar
• Uribe AG, McGwin G Jr, Reveille JD, Alarcon GS. What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading? Autoimmun. Rev.3(4), 321–329 (2004).
   PubMed Web of Science ®Google Scholar
• Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr. Opin. Rheumatol.7(5), 402–408 (1995).
   PubMedGoogle Scholar
• Peschken CA, Esdaile JM. Systemic lupus erythematosus in North American Indians: a population based study. J. Rheumatol.27(8), 1884–1891 (2000).
   PubMed Web of Science ®Google Scholar
• Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology. Lupus9(5), 322–327 (2000).
   PubMed Web of Science ®Google Scholar
• Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus10(6), 405–409 (2001).
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang C. The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum.35, 630–640 (1992).
   PubMed Web of Science ®Google Scholar
• Stoll TS, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann. Rheum. Dis.55(10), 756–760 (1996).
   PubMed Web of Science ®Google Scholar
• Bootsma H, Derksen RHWM, Jaegers S et al. Usefulness of the SLICC/ACR Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum.40(S9), S160 (1997).
   Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36 item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care30, 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Ligtenberg G, Derksen RHWM et al. Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual. Life Res.12(6), 635–644 (2003).
   PubMed Web of Science ®Google Scholar
• Leong KP, Kong KO, Thong BY et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford)44(10), 1267–1276 (2005).
   PubMed Web of Science ®Google Scholar
• Basic Types of Economic Evaluation. In: Methods for the Economic Evaluation of Healthcare Programmes. Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW (Eds). Oxford University Press, NY, USA 6–26 (1997).
   Google Scholar
• Koopmanschap MA. Cost-of-illness studies. Useful for health policy? Pharmacoeconomics14(2), 143–148 (1998).
   PubMed Web of Science ®Google Scholar
• Rice DP. Cost of illness studies: what is good about them? Inj. Prev.6(3), 177–179 (2000).
   PubMedGoogle Scholar
• Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. Br. Med. J.320(7245), 1335 (2000).
   PubMed Web of Science ®Google Scholar
• Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Healthcare Programmes. Oxford University Press, Oxford, UK (1987).
   Google Scholar
• Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. Cost-effectiveness in health and medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Gordon C, Clarke AE. Quality of life and economic evaluation in SLE clinical trials. Lupus8, 645–654 (1999).
   PubMedGoogle Scholar
• Merkesdal S, Ruof J, Huelsemann JL et al. Indirect cost assessment in patients with rheumatoid arthritis (RA), comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data. Arthritis Rheum.53(2), 234–240 (2005).
   PubMed Web of Science ®Google Scholar
• Clarke AE, Petri MA, Manzi S et al. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. J. Rheumatol.27, 2597–2604 (2000).
   PubMedGoogle Scholar
• Clarke AE, Petri M, Manzi S et al. The Systemic Lupus Erythematosus Study: absence of a link between health resource use and health outcome. Rheumatology43, 1016–1024 (2004).
   PubMed Web of Science ®Google Scholar
• Panopalis P, Petri M, Manzi S et al. The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being. Rheumatology (Oxford)44(6), 751–755 (2005).
   PubMed Web of Science ®Google Scholar
• Nichol MB, Shi S, Knight TK, Wallace DJ, Weisman MH. Eligibility, utilization, and costs in a California Medicaid lupus population. Arthritis & Rheum.51(6), 996–1003 (2004).
   Google Scholar
• Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and SLE in Germany. Ann. Rheum. Dis.65(9), 1175–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Panopalis P, Petri M, Manzi S et al. The systemic lupus erythematosus tri-nation study: cumulative indirect costs. Arthritis Care Res. (2006) (In press).
   Google Scholar
• Zink A, Fischer-Betz R, Thiele K et al. Healthcare and burden of illness in systemic lupus erythematosus compared to rheumatoid arthritis: results from the National Database of the German Collaborative Arthritis Centres. Lupus13(7), 529–536 (2004).
   PubMedGoogle Scholar
• Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J. Rheumatol.32(4), 721–728 (2005).
   PubMed Web of Science ®Google Scholar
• Partridge AJ, Karlson EW, Daltroy LH et al. Risk factors for early work disability in systemic lupus erythematosus – results from a multicenter study. Arthritis Rheum.40(12), 2199–2206 (1997).
   PubMed Web of Science ®Google Scholar
• Schiffenbauer J, Hahn B, Weisman MH, Simon LS. Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum.50(8), 2415–2422 (2004).
   PubMed Web of Science ®Google Scholar
• Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine71(6), 518–524 (2004).
   PubMed Web of Science ®Google Scholar